Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01791647
Verified February 2013 by Maurizio Guido, Catholic University of the Sacred Heart. Recruitment status was: Recruiting
: February 15, 2013
Last Update Posted
: February 15, 2013
Catholic University of the Sacred Heart
Information provided by (Responsible Party):
Maurizio Guido, Catholic University of the Sacred Heart
The aim of this study is to compare the effects of six months treatment of two insulin-lowering therapies on the clinical and endocrine-metabolic parameters in obese women affected by polycystic ovary syndrome. The study group includes 40 patients, randomly allocated to subgroup A (metformin 1500 mg/day) and subgroup B (myo-inositol 1500 mg/day). The investigations include menstrual pattern and hirsutism score evaluation, hormonal assays, oral glucose tolerance test, euglycemic hyperinsulinaemic clamp and lipid profile at baseline and after six months of treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 35 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
women with Polycystic Ovary Syndrome, diagnosed in accordance with Rotterdam Consensus Conference Criteria 2003;
age 18-35 years.
significant liver or renal impairment;
other hormonal dysfunction (hypothalamic, pituitary, thyroidal or adrenal causes for the clinical signs);
unstable mental illness;
diagnosis of diabetes mellitus or impaired glucose tolerance;
use of drugs able to interfere with gluco-insulinaemic metabolism for at least three months prior to entering the study.